Research Summaries

Sorafenib Stops Growth of Thyroid Cancer When Radioactive Iodine Has Stopped Working

ASCO Annual Meeting
June 2, 2013

In a recent study, researchers found that the drug sorafenib (Nexavar) keeps metastatic differentiated thyroid cancer from worsening when treatment with radioactive iodine has stopped working. Differentiated thyroid cancer is the most common type of thyroid cancer; it is called “differentiated” because the cancerous thyroid cells look like normal thyroid cells when viewed under a microscope. Metastatic cancer means the thyroid cancer has spread outside of the thyroid.

Adding Bevacizumab to Initial Chemoradiation for Glioblastoma Does Not Lengthen Lives

ASCO Annual Meeting
June 2, 2013

In a new study, researchers found that adding bevacizumab (Avastin) to first-line (first treatments given) chemoradiation therapy did not lengthen the lives of patients with a common and aggressive type of brain tumor called glioblastoma. Chemoradiation therapy is a combination of chemotherapy, which is the use of drugs to kill cancer cells, and radiation therapy, which is the use of high energy x-rays or other particles to kill cancer cells.

Bevacizumab Lengthens Lives for Patients with Recurrent and Advanced Cervical Cancer

ASCO Annual Meeting
June 2, 2013

According to a recent study, adding the drug bevacizumab (Avastin) to chemotherapy for advanced or recurrent (cancer that has come back) cervical cancer lengthens patients’ lives. Chemotherapy is the use of drugs to kill cancer cells, but it is often ineffective for treating advanced cervical cancer. Bevacizumab is a type of targeted therapy, which is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Pages

Subscribe to RSS - Research Summaries